

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/P TO TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: December 23, 2003 (use as many sheets as necessary)				Complete if Known	
				Application Number	10/649,944
Sheet 1 of 6		Filing Date	08/28/2003		
		First Named Inventor	Ralph M. ELLISON		
		Group Art Unit	1614-1616		
		Examiner Name	Unassigned PAK		
		Attorney Docket Number	077319-0384		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		132,275		Gettings	10/15/1872	
		232,807		Dennett	10/05/1886	
		3,700,498		Kanazawa et al.	10/24/72	
		4,497,780		Barin et al.	02/05/85	
		5,759,837		Kuhajda et al.	06/02/98	
		09/110,366		Lu	Fid. 7/6/98	
		09/189,965		Warrell Jr. et al.	Fid. 11/10/98	
		06/702,611		Zhang	Fid. 8/23/06	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
			JP-51-88620			03/08/76		
			WO 95/01789			1/19/95		
			CN 1133725 A			10/23/96		
			CN 1131037 A			9/18/96		
			CN 1122700 A			5/22/96		
			CN 1081104 A			1/26/94		
			CN 1119113 A			3/27/96		
			CN 1061908 A			6/17/92		
			CN 1121807 A			5/8/96		
			CN 1079391 A			12/15/93		
			WO 94/02108			2/3/94		
			FR 2 539 993 A1			3/31/94		
			DE 43 17 331 A1			12/1/94		
			WO 95/22336			8/24/95		
			LV 11667 B			6/20/97		
			JP 51-88620			3/8/76		
			CN 1061908A			6/17/92		
			CN 1081104A			1/26/94		
			WO 94/02108			2/3/94		
			FR 2 539 993 A1			3/31/94		
			WO 95/01789			1/19/95		
			WO 95/22336			8/24/95		
			CN 1119113A			3/27/96		
			CN 1121807 A			5/8/96		
			CN 1122700 A			5/22/96		
			CN 1131037 A			9/18/96		
			CN 1133725 A			10/23/96		

Examiner Signature		Date Considered	12/9/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: December 23, 2003 (use as many sheets as necessary)			Application Number	10/649,944	
			Filing Date	08/28/2003	
			First Name of Inventor	Ralph M. ELLISON	
			Group Art Unit	4644-1616	
			Examiner Name	Unassigned PAIC	
Sheet	2	of	6	Attorney Docket Number	077319-0384

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
		"Arsen (III) - Sulfid As ₂ S ₂ ", Gmelin's Arsenic, 8 th Edition, 17:422-433, 1952.		
		"Diarsendisulfid As ₂ S ₂ ", Gmelin's Arsenic, 8 th Edition, 17:412-422, 1952.		
		"Goodman & Gilman's The pharmacological basis of therapeutics", 9 th Edition, McGraw-Hill, Health Professions Division, pp. 1659-1662 (Date unknown).		
		"Inorganic Arsenic Compounds Other Than Arsine Health and Safety Guide, Health and Safety Guide No. 70", WHO, Geneva, 1992		
		"Xionghuang Realgar", Chinese Pharmacopia (1), Guangdong Science and Technology Publishing House, China, pp. 298-299, 1995		
		Akao et al. "Arsenic Induces Apoptosis in B-cell Leukemic Cell Lines in Vitro: Activation of Caspases and Down-regulation of Bcl-2 Protein", British J of Hematology, 102. 1055-1060, 1998.		
		Andre et al., "The PML and PML/RAR α Domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic", Experimental Cell Research, 229:253-260, 1996.		
		Arsenic, Environmental Health Criteria 18, Geneva: WHO, 1981		
		Chemical Abstract, 63-Pharmaceuticals 11:317, #111:219272j and 111:219276p, 1987-1991.		
		Chen et al., "In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As ₂ O ₃) in the treatment of acute promyelocytic Leukemia: As ₂ O ₃ induces NB ₄ cell apoptosis with down regulation of Bcl-2 expression and modulation of PML-RAR α /PML proteins", Blood 88(3): 1052-1061, 1996		
		Chen et al., "Use of Arsenic Trioxide (As ₂ O ₃) in the Treatment of Acute Promyelocytic Leukemia (APL): I. As ₂ O ₃ Exerts Dose-Dependent Dual Effects on APL Cells" Blood 89(9):3345-3353, 1997		
		Chung et al., "Influence for Carcinoma Cell and Lymphatic cell of Acetyl Arsonate", Yakhak Hoeji 40(5):599-607, 1996.		
		Cutler et al., Article IV, American Journal of the Medical Sciences, pp. 74-84. (Date unknown).		
		Cuzick et al., "Medicinal arsenic and internal malignancies", Br. J. Cancer, 45:904-911, 1982		


Examiner Signature		Date Considered	12/9/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/649,944
Date Submitted: December 23, 2003		Filing Date	08/28/2003
(use as many sheets as necessary)		First Named Inventor	Ralph M. ELLISON
		Group Art Unit	4614-1616
		Examiner Name	Unassigned - PAK
Sheet	3 of 6	Attorney Docket Number	077319-0384


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		De The, "L'oxyde d'arsenic: après l'acide retinoïque, un nouveau traitement cible de la leucémie aigue promyelocytaire" medicine/sciences; 13: 867-71, 1997	
		Dictionary of Inorganic Compounds, Vol. 1, Ac-C ₁₀ , IC-000667-IC-000671 (date unknown).	
		Flamigni et al., "Effect of Sodium Arsenite on the Induction and Turnover of Ornithine Decarboxylase Activity in Erythroleukemia Cells" Cell Biochemistry and Function 7:213-217, 1989	
		Fluka, 1995/96 Catalog: 152-153	
		Forkner et al., "Arsenic as a therapeutic agent in chronic myelogenous leukemia", Jour. A.M.A. 97(1)3-5, 1931.	
		Germolec et al., "Arsenic induces over expression of growth factors in human keratinocytes", Toxicology and Applied Pharmacology, 141:308-318, 1996.	
		Huang et al., 1995, "The Clinical Study of QINGDAI Tablet For Treating Acute Promyelocytic Leukemia" China Magazine of Hematology, 16(1):26.	
		Ishinishi N. et al., "Study on Chronic Toxicity of Arsenic Trioxide in Rats with Special Reference to the Liver Damages" Fukuoka Acta Medicine, 71:27, 1980.	
		Kasper et al., "Hepatic Angiosarcoma and bronchioloalveolar carcinoma induced by Fowler's solution", JAMA 252(24):3407-3408, 1984.	
		Kerkvliet et al., "Immunotoxicology Studies of Sodium Arsenate-effects of Exposure on Tumor Growth and Cell-mediated Tumor Immunity", J. Environmental Pathology and Toxicology 4:65-79, 1980.	
		Kong et al., "Comparative Activity of Melarsoprol and Arsenic Trioxide in Chronic B-Cell Leukemia Lines", Blood 90(2):562-570, 1997.	
		Kwong et al., "Delicious Poison: Arsenic Trioxide for the treatment of Leukemia", Blood 89:3487-8, 1997.	
		Lee et al., "Induction of Gene Amplification by Arsenic", Science, 241: 79-81, 1988.	
		Li et al. "Traditional Chinese and Western Medicine in the Treatment of 27 Patients with Malignant Lymphoma", Chinese J. Oncology, 10:61-62, 1988.	
		Lu et al., "Effective treatment of AML-M3 (APL) and their remission maintenance with Realgar: A pilot clinical and laboratory study on 38 patients", Blood 90(10 Suppl. 1 part 1):416A, #1849, 1997.	

Examiner Signature		Date Considered	12/9/05
---------------------------	--	------------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: December 23, 2003 (use as many sheets as necessary)		Application Number	10/649,944		
		Filing Date	08/28/2003		
		First Named Inventor	Ralph M. ELLISON		
		Group Art Unit	1614 1616		
		Examiner Name	Unassigned PAK		
Sheet	4	of	6	Attorney Docket Number	077319-0384


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		Lu et al., "Study of Realgar in the treatment of acute promyelocytic Leukemia (APL)- a pilot clinical and laboratory study on 38 patients", China-Korea Medical Conference '97 1997.	
		Mervis, "Ancient remedy performs new tricks", Science 273: 578, 1996.	
		Monfardini et al., "Survival in chronic myelogenous leukemia: Influence of treatment and extent of disease at diagnosis", Cancer, 31:492-501, 1973.	
		Neubauer, "Arsenic Cancer: a review", Arsenical Cancer, Arsenic Committee of the Medical Research Council, pp. 192-251, 1947.	
		Pershagen et al., "On the pulmonary tumorigenicity of arsenic trisulfide and calcium arsenate in hamsters", Cancer Letter, 27:99-104, 1985.	
		Pories et al., "Trace Elements that Act to Inhibit Neoplastic Growth", Annals New York Academy of Sciences, 199: pp 265-273, 1972.	
		Qi and Bi, "Method for removing As ₂ O ₃ from Realgar", Chung Yao Tung Pao, 8(5):21-22, 1983	
		Reichl et al., "Effect of Arsenic on Cellular Metabolism after Single or Repeated Injection in Guinea Pigs", Arch. Toxicol., Suppl. 13. p. 363-65, 1989.	
		Remington's Pharmaceutical Sciences, Mach Publishing Co., Easton, PA, p. 1570-80, 1990.	
		Schenk, Handbook of Preparative Inorganic Chemistry, 1:603, G. Brauer, Ed., Academic press, New York, 2 nd Ed. 1963.	
		Shen et al., "Use of arsenic trioxide (As ₂ O ₃) in the treatment of acute promyelocytic Leukemia (APL):II. Clinical efficacy and pharmacokinetics in relapsed patients", Blood 89(9):3354-3360, 1997.	
		Shibuya, "Studies on Experimental Arsenious Acid Poisoning", Tokyo Jikeikai Ika Daigaku Zasshi 86(4):653, 1971.	
		Soignet et al., "Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide", J of Medicine 339:19, 1998.	
	Stephens et al., "The therapeutic effect of solution of potassium arsenite in chronic myelogenous leukemia" Ann. Intern. Assoc 9:1488-1502, 1936.		
		Suehiro Shimotsuura et al., "Studies on the Antineoplastic Actions of As ₂ O ₃ ", Shikwa Gakuho 86:1237-1253, 1986.	

Examiner Signature		Date Considered	12/9/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO & TRADEMARK OFFICE		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: December 23, 2003 (use as many sheets as necessary)		Application Number	10/649,944		
		Filing Date	08/28/2003		
		First Named Inventor	Ralph M. ELLISON		
		Group Art Unit	1614 1616		
		Examiner Name	Unassigned PAK		
Sheet	5	of	6	Attorney Docket Number	077319-0384

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		Sun et al., "Ai Ling #1 and Traditional Chinese Medicine in the Treatment of 32 patients with Acute Promyelocytic Leukemia", Chinese J. of Traditional Chinese and Western Medicine 1(3), 1992.	
		Treleaven et al., "Arsenic and Ayurveda" Leukemia and Lymphoma 10:343-345, 1993.	
		USP Dictionary of USAN and International Drug Names, United States Pharmacopeial Conventions, Inc. Rockville, MD, p. 59, 11/1994	
		Wang et al., "Arsenic and the Treatment of Leukemia", J. Harbin Medical Univ. 31:5 428-429, 1997.	
		Wang et al., "Studies on chemically preventing Leukemia", Chung Hua Chung Liu Tsa Chih, 11(3):207-210, 1989.	
		Xiang et al., 1995, "60 Cases of Treating Acute Promyelocytic Leukemia by QINGDAI Tablet", Med. J. Chin. PLA 20(3):227-229.	
		Yamamoto et al. "Tumorigenicity of inorganic arsenic compounds following intratracheal instillations to the lungs of hamsters", Int. J. Cancer, 40:220-223, 1987.	
		Yuan et al., "Research on traditional methods for Purifying Realgar", Chung Yao Tung Pao, 13(8): 23-26, 1988	
		Yuan et al., "Exploring methods for purifying Realgar", Chung Yao Tung Pao, 13(8): 17-21, 1988.	
		Zhang et al., "Traditional Chinese and Western Medicine in the Treatment of 27 patients with Malignant Lymphoma" Chinese J. Oncology 10:61-62, 1988.	
		Zhang et al. "Treatment of Acute Promyelocytic Leukemia with "713": Clinical Observations and Study of Action Mode on 117 Patients", J. Harbin Medical Univ. 29(3): 243, 1995.	
		Zhang et al., "Clinical Study on the Treatment of Acute Promyelocytic Leukemia with Ai Ling #1", J of Traditional Chinese and Western Medicine 4(1):19, 1984.	
		Zhang et al., "Treatment of Acute Promyelocytic Leukemia with Intravenous Arsenic Trioxide", Chinese J. of Hematology 17(2): 1996.	
		Zhang et al. "Discussion on methods for removing As involving use of yogurt", Zhongguo Zhongyao Zaazhi, 20(9): 537, 1995.	
			Zhu et al., "Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia", Proc. Natl. Acad. Sci. 94:3978-3983, 1997. — 1997.

Examiner Signature		Date Considered	12/9/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/P-16 TRADEMARK OFFICE				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: December 23, 2003 (use as many sheets as necessary)				Application Number	10/649,944
				Filing Date	08/28/2003
				First Named Inventor	Ralph M. ELLISON
				Group Art Unit	1614
				Examiner Name	Unassigned <i>1616 PAK</i>
Sheet	6	of	6	Attorney Docket Number	077319-0384

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		"Letter on Historical Facts Regarding the Development of Ai Ling. No. 1 and the Clinical Use of Arsenic Trioxide in the Treatment of Acute Promyelocytic Leukemia and a Study of its Mechanism" Heilongjiang Branch of the Chinese Medical Association, March 27, 1998.	
		Wang et al., "Arsenic Trioxide and Melarsprol Induced Programmed cell death in myeloid leukemia cell lines and function in PML and PNL-RARα Independent Manner," Blood, 92(5):1497-1504, 1998.	
		Flamigni et al., "Effect of Sodium Arsenite on the Induction and Turnover of Ornithine Decarboxylase Activity in Erythroleukemia Cells", Cell Biochemistry and Function Vol. 7:213-217 (1989) © John Wiley & Sons Ltd. 1989	
		Reichi et al., "Effect of Arsenic on Cellular Metabolism After Single or Repeated Injection in Guinea Pigs" Arch. Toxicol., Suppl. 13, 363-365 (1989) © Springer Verlag 1989	
		Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton PA, Chapter 85, pp. 1570-80, 1990.	
		"Inorganic Arsenic Compounds other than Arsine Health and Safety Guide, Health and Safety Guide No. 70, WHO, Geneva 1992.	
		Sun et al., "Ai Ling #1 and Traditional Chinese Medicine in the Treatment of 32 Patients with Acute Promyelocytic Leukemia, Chinese J. of Traditional Chinese and Western Medicine, pp. 170-171, Vol. 12, No. 3, 1992.	
		Treleaven et al., "Arsenic and Ayurveda", Leukemia and Lymphoma, Vol. 10, pp. 343-345 © Harword Academic Publishers GmbH 1993	
		USP Dictionary of USAN and International Drug Names, United States Pharmacopeial Conventions, Inc., Rockville Md., p. 59, November 1995	
		Fluka 1995/96 Catalog, pp. 152-153 July 1995	
		Wang et al., "Arsenic and the Treatment of Leukemia" J. Harbin Medical University, Vol. 31, No. 5, October 1997	


Examiner Signature		Date Considered	12/9/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 10/649,944 INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 10, 2004 (use as many sheets as necessary)		Complete if Known	
		Application Number	10/649,944
		Filing Date	08/28/2003
		First Named Inventor	Ralph M. ELLISON
		Group Art Unit	4644-1616
		Examiner Name	Unassigned-PAK
Sheet	1 of 2	Attorney Docket Number	077319-0384

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
			FR 2 699 820		Eric PIGNOT	12/24/1992		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
		International Search Report of EP 03019594 (Dated 11/4/2003).		
		Matthew BLOCK et al., "Biological Studies with Arsenic IV. The Histopathologic Effect of Arsenic Upon the Hematopoietic Tissues of Patients with Leukemia", The Journal of Laboratory and Clinical Medicine, Vol. 41, No. 4, 4/1953, pp. 499-515.		
		P. ROUSELLOT et al., "Arsenic derivatives: Old drugs for new indications!", Les Derives Arsenicaux: De Vieux Medicaments Pour Des Indications Renouvelees", Hematologie, Vol. 4, no. 3, 5/1998, pp. 95-97.		
		P. ROUSELLOT et al., "Arsenic trioxide (AS2O3) and Melarsoprol induce myeloma cell apoptosis in vitro with a preferential effect on tumoral cells in patients' bone marrow", BLOOD, vol. 90, no. 10, 11/15/1997, page 325A.		
		Z. XIE et al., "Melarsoprol and arsenic trioxide increase cell death on doxorubicin-resistant human leukemia and myeloma cells by regulating expression of BCL-2 apoptosis regulatory family", BLOOD, vol. 90, no. 10, 11/15/1997, pp. 495 A.		
		DATABASE EPODOC 'Online! European Patent Office, the Hague, NL., CN1180563, 5/6/1998, Zhao QINGTUAN: XP002260136 *abstract*.		
		International Search Report of EP 03019595 (Dated 10/24/2003).		
		Edward B. SILBERSTEIN, "Radionuclide Therapy of Hematologic Disorders", Seminars in Nuclear Medicine, Vol. 9, No. 2, 4/1979, pp. 100-107.		
		David A. SEARS MD, "History of the Treatment of Chronic Myelocytic Leukemia", American Journal of the Medical Sciences, Vol. 296, No. 2, 8/1988, pp. 85-86.		

Examiner Signature		Date Considered	12/9/05
--------------------	--	-----------------	---------



*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 10, 2004 (use as many sheets as necessary)		Application Number	10/649,944
		Filing Date	08/28/2003
		First Named Inventor	Ralph M. ELLISON
		Group Art Unit	1614 1616
		Examiner Name	Unassigned PAK
Sheet	2	of	2
		Attorney Docket Number	077319-0384

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issuë number(s), publisher, city and/or country where published.	T ⁶
		Zhi-Xiang SHEN et al., "Use of Arsenic Trioxide (As ₂ O ₃) in the Treatment of Acute Promyelocytic Leukemia (APL); II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients", Blood, Vol. 89, No. 9, 5/1997, pp. 3354-3360.	
		International Search Report of EP 03019628 (Dated 10/27/2003).	
		W. ZHANG et al., "The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms", Leukemia (1998), vol. 12, no. 9, 9/1998, pp. 1383-1391.	
		John G. KIDD, "EFFECTS OF ARSENIC AZOPROTEINS ON MOUSE LYMPHOMA CELLS IN VIVO* With Observations on the Effects of Other "Anti-Lymphoma" Agents and On the Susceptibility to these Effects of Lymphoma Cells of Various Types", Journal of Experimental Medicine, vol. 108, 1958, pp. 665-684.	
		Jacques DEBRAY, "Treatment of Hodgkin's Disease", Therapie, vol. 9, 1954, pp. 106-118.	
		G. LOTTI, "Abandonment of arsenic in medical therapy of malignant granuloma (Hodgkin's disease): is it justified?" Revue Medicale Du Moyen-Orient, vol. 24, no. 2, 3/1967 pp. 110-111.	
		International Search Report of EP 03029713 (Dated 3/31/2004).	
		S. ROSNER, "Immunological Enhancement of Chemotherapy in Advanced Brain Cancer", ACTA. NEUROL. LATINOAMER. Vol. 21, No. 4, 1975, pp. 126-132.	
		S. SHIMOTSUURA, "STUDIES ON THE ANTINEOPLASMIC ACTIONS OF AS ₂ O ₃ " Shika Gakuho - Journal of Tokyo Dental College Society, vol. 86, no. 8, 1986, pp. 1237-1253.	
		P. ZHANG et al., "Treatment of Acute Promyelocytic Leukemia with Intravenous Arsenic Trioxide" Zhonghua Xueyexue Zazhi - Chinese Journal of Hematology, vol. 17, no. 2, 2/1996, pp. 58-60.	
		D.A. Sears, "History of the Treatment of Chronic Myelocytic Leukemia", American Journal of Medical Sciences, vol. 296, no. 2, 8/1988, pp. 85-86.	
		Y.L. KWONG et al., "Delicious Poison: Arsenic Trioxide for the Treatment of Leukemia", Blood, vol. 89, no. 9, 5/1997, pp. 3487-3488	
			Edward B. SILBERSTEIN, "Radio nuclide Therapy of Hematologic Disorders", Seminars in Nuclear Medicine, vol. 9, no. 2, 4/1979, pp. 100-107.

Examiner Signature		Date Considered	12/9/2005
--------------------	---	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: October 12, 2004 Use as many sheets as necessary		Complete if Known Application Number: 10/649,944 Filing Date: 8/28/2003 First Named Inventor: Ralph M. ELLISON Group Art Unit: 1614 1616 Examiner Name: Unassigned PAK Attorney Docket Number: 077319-0384	
SHEET 1 of 1			

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		6,720,011		ZHANG	4/13/2004	
		6,770,304		WARRELL, Jr. et al.	8/3/2004	
		6,733,792		LU	5/11/2004	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C1	International Search Report of EP 0 400 784 7 (Dated 6/16/2004).	
	C2	Kunio KITAMURA et al., "New Retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation", Cancer Chemother Pharmacol, (1977), 40 (Suppl) pp. S36-S41.	
	C3	Zhu CHEN et al., "Acute Promyelocytic Leukemia: Cellular and Molecular Basis of Differentiation and Apoptosis", Pharmacol. Ther., Vol. 76, Nos. 1-3, pp. 141-149, 1997.	
	C4	DATABASE MEDLINE Online! US National Library of Medicine (NLM), Bethesda, MD US; August 25, 1997, Melino G. et al., "Retinoic acid receptors alpha and gamma mediate the induction of "tissue" transglutaminase activity and apoptosis in human neuroblastoma cells", XP002284763, Database accession no. NLM9281352 *ABSTRACT	
	C5	DATABASE MEDLINE Online! US National Library of Medicine (NLM) Bethesda, MD, US; July 1997, Cooper M. P. et al., "All-trans retinoic acid induced gene expression and growth inhibition in head and neck cancer cell lines" XP002284764 Database accession no. NLM9307717 *ABSTRACT & Oral Oncology, July 1997, vol. 33, no. 4, pp. 270-274, ISSN: 1368-8375.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.